Frankfurt - Delayed Quote EUR

Atossa Therapeutics, Inc. (YAG2.F)

Compare
0.8510
+0.1510
+(21.57%)
At close: January 31 at 2:07:53 PM GMT+1
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for YAG2.F

Recent News: YAG2.F

View More
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591
GlobeNewswire yesterday
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025
GlobeNewswire 8 days ago
Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer

Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer
GlobeNewswire 25 days ago
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Zacks last month
Atossa Therapeutics to present poster on Z-endoxifen at SABCS

Atossa Therapeutics to present poster on Z-endoxifen at SABCS
TipRanks last month
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
GlobeNewswire last month
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
GlobeNewswire last month
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
GlobeNewswire last month
Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research
GlobeNewswire last month
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research
GlobeNewswire 2 months ago
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium
GlobeNewswire 2 months ago
View More

Related Tickers

W2J.F Carisma Therapeutics, Inc.
0.5940
0.00%
 
2X10.F ABIVAX Société Anonyme
5.55
+0.91%
 
BX2.F BioXcel Therapeutics, Inc.
0.3289
+10.00%
 
PSH.F Sernova Corp.
0.1363
+0.22%
 
W1H.F Onco-Innovations Limited
1.3300
+2.31%
 
IFRX InflaRx N.V.
2.4100
+1.69%
 
CARM Carisma Therapeutics, Inc.
0.4598
-7.86%
 
HEPA Hepion Pharmaceuticals, Inc.
0.1795
-3.80%
 
PPCB Propanc Biopharma, Inc.
9.00
0.00%
 
DWTX Dogwood Therapeutics, Inc.
12.49
-2.12%